Merrimack Pharmaceuticals Inc. (MACK) was one of the Russell 2000's biggest losers for Wednesday January 06 as the stock slid 8.95% to $7.12, a loss of $-0.7 per share. Starting at an opening price of $7.65 a share, the stock traded between $7.04 and $7.70 over the course of the trading day. Volume was 943,688 shares over 6,409 trades, against an average daily volume of 1.44 million shares and a total float of 115.57 million.
The losses send Merrimack Pharmaceuticals Inc. down to a market cap of $822.89 million. In the last year, Merrimack Pharmaceuticals Inc. has traded between $13.84 and $7.21, and its 50-day SMA is currently $8.76 and 200-day SMA is $10.47.
Merrimack Pharmaceuticals Inc is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer.
Merrimack Pharmaceuticals Inc. is based out of Cambridge, MA and has some 306 employees. Its CEO is Robert J. Mulroy.
For a complete fundamental analysis analysis of Merrimack Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for MACK. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.